Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours.

The article discusses the recent approval of a cell therapy called lifileucel for the treatment of melanoma. Lifileucel uses a patient's own tumor-infiltrating T lymphocytes (TILs) to target and treat melanoma. This approval marks a significant advancement in cancer treatment, as it is the first cell therapy to be approved for a solid tumor. Clinical trials have shown that lifileucel has a response rate between 30% and 50%, making it a valuable addition to the treatment options for melanoma patients who do not respond to other therapies. However, there are still challenges to overcome, such as the need for a surgical procedure to isolate TILs and the exclusion of patients with certain conditions. Ongoing research is focused on improving the effectiveness and specificity of T-cell therapies for melanoma. [Extracted from the article]